These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26502926)

  • 21. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Fiala O; Pesek M; Skrickova J; Kolek V; Salajka F; Tomiskova M; Satankova M; Kultan J; Kuliskova J; Svaton M; Hrnciarik M; Hejduk K; Chloupkova R; Topolcan O; Hornychova H; Nova M; Ryska A; Finek J
    Tumour Biol; 2017 Feb; 39(2):1010428317691186. PubMed ID: 28218046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system.
    Pérez-Moreno MA; Cotrina-Luque J; Galván-Banqueri M; Flores-Moreno S; Bautista-Paloma FJ; Calleja-Hernández MÁ
    J Chemother; 2015; 27(6):371-7. PubMed ID: 25971603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Yoshida T; Okamoto T; Yano T; Takada K; Kohno M; Suda K; Takenoyama M; Oda Y; Maehara Y
    Anticancer Res; 2016 Dec; 36(12):6319-6326. PubMed ID: 27919952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
    Visser S; Hou J; Bezemer K; de Vogel LL; Hegmans JPJJ; Stricker BH; Philipsen S; Aerts JGJV
    BMC Cancer; 2019 May; 19(1):440. PubMed ID: 31088547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
    Bepler G; Sommers KE; Cantor A; Li X; Sharma A; Williams C; Chiappori A; Haura E; Antonia S; Tanvetyanon T; Simon G; Obasaju C; Robinson LA
    J Thorac Oncol; 2008 Oct; 3(10):1112-8. PubMed ID: 18827606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
    Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
    BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Sørensen JB
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):645-52. PubMed ID: 24562672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer.
    Yoon JY; Park CK; Choi YD; Oh IJ; Kim YC
    Thorac Cancer; 2019 Apr; 10(4):942-949. PubMed ID: 30864258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.
    Maus MK; Mack PC; Astrow SH; Stephens CL; Zeger GD; Grimminger PP; Hsiang JH; Huang E; Li T; Lara PN; Danenberg KD; Gandara DR
    J Thorac Oncol; 2013 May; 8(5):582-6. PubMed ID: 23470290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
    Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
    Zhou H; Dai Y; Zhu L; Wang C; Fei X; Pan Q; Chen J; Shi X; Yang Y; Tao X; Shi P
    J Int Med Res; 2016 Feb; 44(1):89-98. PubMed ID: 26740498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).
    Alvarez-Fernandez C; Perez-Arnillas Q; Ruiz-Echeverria L; Rodriguez-Rubi D; Sanchez-Lorenzo L; Li-Torres W; Izquierdo-Manuel M; Berros JP; Luque-Cabal M; Jimenez-Fonseca P; Villanueva-Palicio N; Esteban-Gonzalez E
    Invest New Drugs; 2014 Apr; 32(2):377-81. PubMed ID: 23912258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.
    Dong H; Bao D; Guo X; Hu J; Li X; Wan S; Xing J
    Tumour Biol; 2015 Sep; 36(9):7151-7. PubMed ID: 25877757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
    Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study.
    Zhu W; Røe OD; Wu C; Li W; Guo R; Gu Y; Liu Y; Shu Y; Chen X
    J Chemother; 2015 Aug; 27(4):221-6. PubMed ID: 25735792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
    Han Y; Wang XB; Xiao N; Liu ZD
    Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
    Fukuda S; Oguri T; Kunii E; Sone K; Uemura T; Takakuwa O; Maeno K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
    Lung Cancer; 2016 Dec; 102():15-20. PubMed ID: 27987582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Lima A; Seabra V; Martins S; Coelho A; Araújo A; Medeiros R
    Mol Biol Rep; 2014 May; 41(5):3349-57. PubMed ID: 24554028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.